

Patient Disease: Treatment of canine multicentric lymphoma

Study Title: Assessing the efficacy and tolerability of daunomustine in dogs with multicentric lymphoma.

Purpose of Study/Background/Objectives: The purpose of this study is to evaluate the efficacy of a novel chemotherapy drug, daunomustine, in treatment naïve dogs with multicentric lymphoma.

Inclusion Criteria:

- Cytologic or histologic diagnosis of multicentric lymphoma from a peripheral node
- Treatment naïve including steroids
- Adequate organ function
- Favorable performance status

Exclusion Criteria:

- Dogs weighing < 4 kgs or that are < 1 yr of age
- Indolent or small cell lymphoma
- Previous chemotherapy or steroid therapy (use of steroid-containing topicals allowed)
- Liver values > 4x normal or elevated total bilirubin
- BUN and Creatinine > 1.5x normal. Minerals (excluding calcium), electrolytes, and albumin within 20% of the margins of normal range. Hypercalcemic dogs can enroll if they feel well and are otherwise eligible.
- Thrombocytopenia < 100,000, Neutropenia < 2,000
- Dilated cardiomyopathy (left ventricular dilation and systolic dysfunction) or history of congestive heart failure

Eligibility Diagnostics:

- CBC, Chemistry Panel, U/A
- Cytology or histopathologic diagnosis of lymphoma

Treatment/Protocol: The patient will receive up to 5 doses of IV daunomustine given every 14 days. At each treatment, dose will be escalated within the patient based on response. Patients will return to the U of I seven days after each treatment for bloodwork and exam as deemed necessary. Following completion of the 5 doses the patient will return every 2 weeks for 2 visits, then every 2 months for 2 visits, then every 3 months long term, where exam and lab work will be performed. A single dose of l-asparaginase will be given as deemed appropriate during the protocol for patients not in complete remission. Patients will be treated on an outpatient basis and go home each day. Patients will be removed from trial and offered standard of care if they are assessed as having progressive disease.

Owner Commitments: Owner Commitments:

- Pet owners are responsible for the initial exam and diagnostics to determine eligibility
- Pet owners are expected to make and keep all appointments associated with the study
- Pet owners are responsible for all costs associated with unrelated medical conditions

Compensation:

- This is a fully funded trial once the pet is deemed eligible
- In the event of adverse events, partial funding to cover these costs is available if treatment is pursued at the University of Illinois.
- After completion of trial participation (or removal from trial due to stable or progressive disease) a \$1,000 incentive to be used at the U of I VTH will be awarded.

Contact Us: Our trials team recommends scheduling an on-site appointment to assess the pet's eligibility. We do not require a referral. The professional fee for the consultation is approximately \$250 and does not include tests, medications or treatments that may be recommended at the appointment. **To schedule please call 217-333-5300.**

We would like the opportunity to review the pet's records from the veterinarian. After the appointment has been made the records can be emailed to medrec@illinois.edu or faxed to 217-244-2554.

If you have further questions, please contact our Clinical Trials Coordinator, Rebecca Kameron, at (217) 300-6453 or rmoss81@illinois.edu

Referring veterinarians and client calls are welcome.

Please check our up-to-date website to see if this trial is still active and enrolling.

<https://vetmed.illinois.edu/research/clinical-trials/>

